The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for game-changing treatments and substantial returns is clear, the linked risks are also considerable. Many o… Read More